Last reviewed · How we verify
NCT05525754
Computed Tomography-Guided Nasotracheal Intubation Procedure
trial testing computed tomography-guided nasotracheal intubation in Computed Tomography-guided Nasotracheal Intubation in 60 participants. Completed in 1 January 2022.
1 January 2021
Quick facts
| Lead sponsor | TC Erciyes University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 January 2019 |
| Primary completion | 1 January 2021 |
| Estimated completion | 1 January 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- computed tomography-guided nasotracheal intubation
Conditions studied
- Computed Tomography-guided Nasotracheal Intubation — all drugs for Computed Tomography-guided Nasotracheal Intubation →
- The Space Where the Tube Will be Passed in the Internal Nasal Valve Region — all drugs for The Space Where the Tube Will be Passed in the Internal Nasal Valve Region →
Sponsor
TC Erciyes University
Who can join
Adults 18 to 65, any sex, with Computed Tomography-guided Nasotracheal Intubation or The Space Where the Tube Will be Passed in the Internal Nasal Valve Region. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Nasotracheal intubation can lead to severe complications like epistaxis with excessive bleeding. The advancement difficulty of the tube faced during nasal intubation is one of the fundamental causes of this condition. The present study aimed to evaluate the effectiveness of Computed tomography-guided nasotracheal intubation in predicting tube advancement difficulty and preventing epistaxis. Material and Methods: 60 maxillofacial surgery patients were included in the study. The space where the tube will be passed in the internal nasal valve region was measured horizontally (distance between inferior concha and septum) and vertically (distance between inferior concha and hard palate) by Computed Tomography. The patients were divided into two groups, 'easy' (n=28) or 'difficult' (n=32), according to the effort required to advance the tube through the nasal passage. ROC analysis was performed, and cut-off values were determined to reveal the distance values at which difficulty may be experienced while advancing the tube. The cut-off values were 1.09 cm and 0.39 cm for the vertically and horizontally distances, respectively.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness Of Computed Tomography-Guided Nasotracheal Intubation Procedure On Predicting Tube Advancement Difficulty And Preventing Epistaxis: A Prospective Case-Control Study.
Yasli SO, Canpolat DG, Baydan E, Demirbas AE. · · 2023 · cited 3× · PMID 37876056 · DOI 10.47391/jpma.8034
Verify or expand the search:
- PubMed search for NCT05525754
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other TC Erciyes University trials
Trials by the same sponsor.
- NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
- NCT07529964 — MMP-2/3 and Periapical Healing Outcomes · not yet recruiting
- NCT07526831 — Comparison of the Analgesic Efficacy of Adductor Canal Block and Combined Adductor Canal Block Plus IPACK Block in Knee · recruiting
- NCT07371806 — EFFETCS OF MİNDFULNESS-BASED STRESS REDUCTION İN WOMEN WİTH CORONARY ARTERY DİSEASE · NA · not yet recruiting
- NCT07499947 — Predicting Spinal Hypotension in Cesarean Section · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05525754 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TC Erciyes University
- Last refreshed: 2 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525754.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing